Market Advantage Of 'MR-Conditional' Device Labeling Fades
Abbott Laboratories and Boston Scientific recently logged approvals that bring the firms closer to parity with Medtronic in being able to market their cardiac rhythm management devices as compatible with MRI scans. But CMS, the US Medicare agency, is currently considering a coverage policy that make so-called "MR-conditional" product labeling less significant.
You may also be interested in...
Major Trial Of Medtronic's ECG Belt Begins
The company announced the launch of a US randomized trial of its ECG Belt Research System, a tool to optimize cardiac resynchronization.
Medicare MRI Restrictions Removed For Cardiac Device Patients
The US Centers for Medicare and Medicaid Services followed through with a plan to expand its national coverage policy for MRI scans, removing contraindications and clinical-study requirements for patients with pacemakers, implantable cardioverter defibrillators and other cardiac rhythm devices.
Earnings Winners & Losers: ABMD, BSX, EW, ABT Pump Money Into Cardio; SYK, ZBH Innovate Ortho Surgery
Most of the major medical device companies have reported sales and earnings for the last three months of 2017 and the full year. Cardiovascular companies are succeeding with new technology while continuing to grow revenues from established technologies, especially in emerging markets. Orthopedic firms are looking to new technology, like surgery robots and neurostimulation, to differentiate themselves from the competition and improve profits.